BPC-157: What FDA Actually Said About It

BPC-157 is sold everywhere and approved nowhere. It is not an FDA-approved drug for any condition, and it is not on the list of substances a compounding pharmacy may lawfully use. What FDA has actually put on the record about it is more specific than either the marketing or the alarm around it, and it is worth reading precisely.

The short version: FDA reviewed BPC-157 for the compounding list, wrote down why it was concerned, and the nomination was withdrawn before it ever got on. That leaves the substance outside the compounding system entirely — which is why what you can buy comes labeled as a research chemical rather than as medicine.

What FDA put on the record

FDA maintains a page titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.^[1] Substances that raise concerns during review go into what FDA calls category 2. BPC-157 appears there, in the table of substances nominated but withdrawn — previously in category 2, withdrawn by the party that nominated it.

“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information…”^[1]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

Three separate concerns are packed into that. Immunogenicity — your immune system may react to the peptide itself. Peptide-related impurities — what else ends up in the vial alongside the intended molecule. API characterization — whether anyone can reliably establish that what is in the vial is what the label claims.

What this does and does not mean

The naming problem, which is not academic

FDA has flagged something specific about how these peptides are sold: multiple salts and derivatives, with genuinely different active moieties, circulate commercially under the same common name. Two vials both saying “BPC-157” can contain chemically different substances.

⚠ That breaks the one check a careful buyer thinks they have. Comparing labels tells you nothing if the label is not a chemical identity, and a certificate of analysis is only as good as the party that produced it — which, in this market, is generally the seller.

AOD-9604 sits in the same place

AOD-9604, another peptide sold for fat loss, appears in the same withdrawn table with nearly identical language — immunogenicity, peptide-related impurities, API characterization, and limited safety information. FDA adds one line it does not use for BPC-157: it “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.”^[1]

Ipamorelin acetate, by contrast, is in the active category 2 table — 503B, dated 29 September 2023 — with immunogenicity and unnatural amino acids cited.^[1] These distinctions are small on the page and large in what they mean, which is why this article quotes rather than summarizes.

If you are being sold this alongside a GLP-1

Plenty of telehealth sellers list peptides beside their GLP-1 offerings, and the two are not in the same regulatory position at all. A compounded GLP-1 comes from a licensed pharmacy against a prescription, from a molecule with approved counterparts and published trials. BPC-157 has none of that.

1. Ask which pharmacy compounds it and under what authority. If it is not on the 503A bulks list, a licensed pharmacy compounding it is a question the seller should be able to answer.
2. Treat “research use only” as the answer, not the disclaimer. It means no prescriber, no pharmacy and no accountability.
3. Do not accept a seller’s own certificate of analysis as identity verification, given FDA’s specific point about naming.
4. Tell your prescriber. Whatever else is true, they should know what you are injecting alongside a prescribed drug.

Common questions